Boston Scientific Corp (BSX) KPIs and segments
Close on Nov 17, 2026Market cap $62.36BP/E 17.4Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Boston Scientific · năm tài chính kết thúc December 31 (Calendar Fiscal Year; FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026)
Nhìn nhanh KPI của Boston Scientific: 60 chỉ số vận hành, trong đó có Cardiovascular Segment — Worldwide Net Sales, Interventional Cardiology & Vascular Therapies và Watchman (Left Atrial Appendage Closure, lấy từ 259 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cardiovascular($M)2 | 3,624 | 3,503 | 3,477 | 3,343 | 3,345 | 3,085 | 2,942 | 2,731 | 2,637 | 2,445 | 2,285 | ||
United States($M) | 2,175 | 2,137 | 2,147 | 2,092 | 2,042 | 1,868 | 1,779 | 1,586 | 1,474 | 1,316 | 1,251 | ||
Int'l($M) | 1,449 | 1,366 | 1,329 | 1,251 | 1,303 | 1,218 | 1,163 | 1,145 | 1,163 | 1,129 | 1,034 | ||
BSX Reportable Segments4 | |||||||||||||
United States($M) | 3,294 | 3,224 | 2,960 | 2,593 | 2,466 | 2,258 | |||||||
Europe, Middle East and Africa($M) | 932 | 932 | 793 | 878 | 846 | 773 | 822 | 803 | |||||
Asia-Pacific($M) | 878 | 803 | 802 | 790 | 701 | 684 | 670 | 647 | |||||
Latin America and Canada($M) | 206 | 185 | 175 | 169 | 155 | 159 | 162 | 149 | |||||
MedSurg($M)2 | 1,818 | 1,701 | 1,809 | 1,722 | 1,716 | 1,577 | 1,620 | 1,479 | 1,483 | 1,412 | 1,441 | ||
United States($M) | 1,251 | 1,147 | 1,237 | 1,202 | 1,183 | 1,093 | 1,113 | 1,007 | 992 | 941 | 962 | ||
Int'l($M) | 567 | 554 | 571 | 519 | 534 | 484 | 506 | 472 | 491 | 470 | 479 | ||
Cardiology($M)2 | 2,641 | 2,647 | 2,429 | 2,296 | 2,129 | 2,047 | 1,872 | 1,751 | |||||
United States($M) | 1,687 | 1,640 | 1,491 | 1,403 | 1,269 | 1,166 | 1,017 | 959 | |||||
Int'l($M) | 954 | 1,007 | 938 | 895 | 859 | 881 | 854 | 792 | |||||
Interventional Cardiology & Vascular Therapies($M)2 | 1,333 | 1,244 | 686 | 1,178 | 1,124 | 668 | 661 | 665 | 652 | 614 | |||
Int'l($M) | 746 | 692 | 429 | 679 | 657 | 450 | 449 | 464 | 457 | 426 | |||
United States($M) | 586 | 552 | 256 | 499 | 467 | 216 | 212 | 201 | 195 | 189 | |||
Electrophysiology($M)2 | 916 | 905 | 890 | 865 | 840 | 730 | 649 | 527 | 428 | 300 | 240 | ||
United States($M) | 606 | 603 | 605 | 607 | 587 | 511 | 461 | 366 | 271 | 158 | 111 | ||
Int'l($M) | 310 | 302 | 285 | 258 | 252 | 219 | 188 | 160 | 157 | 143 | 130 | ||
Endoscopy($M)2 | 793 | 736 | 759 | 747 | 737 | 673 | 691 | 678 | 676 | 642 | 646 | ||
United States($M) | 491 | 446 | 464 | 462 | 456 | 420 | 424 | 417 | 415 | 395 | 393 | ||
Int'l($M) | 303 | 290 | 297 | 285 | 281 | 253 | 267 | 261 | 261 | 247 | 251 | ||
Peripheral Interventions($M)2 | 702 | 698 | 656 | 645 | 602 | 590 | 573 | 533 | |||||
United States($M) | 405 | 402 | 376 | 377 | 316 | 308 | 299 | 291 | |||||
Int'l($M) | 297 | 296 | 280 | 268 | 285 | 281 | 274 | 242 | |||||
Urology($M)2 | 684 | 646 | 717 | 682 | 676 | 633 | 630 | 532 | 525 | 513 | 527 | ||
United States($M) | 503 | 465 | 522 | 511 | 499 | 469 | 459 | 379 | 363 | 356 | 362 | ||
Int'l($M) | 181 | 182 | 195 | 171 | 178 | 165 | 170 | 153 | 162 | 157 | 165 | ||
Cardiac Rhythm Management($M)2 | 585 | 578 | 586 | 578 | 590 | 578 | 566 | 561 | 576 | 575 | 553 | ||
United States($M) | 349 | 349 | 359 | 354 | 355 | 358 | 349 | 349 | 352 | 354 | 348 | ||
Int'l($M) | 236 | 229 | 228 | 224 | 235 | 220 | 218 | 213 | 224 | 221 | 204 | ||
Watchman($M)2 | 507 | 506 | 535 | 512 | 486 | 425 | 413 | 380 | 379 | 344 | 344 | ||
United States($M) | 459 | 462 | 485 | 470 | 446 | 390 | 375 | 342 | 342 | 311 | 312 | ||
Int'l($M) | 48 | 44 | 50 | 43 | 40 | 34 | 38 | 38 | 36 | 33 | 32 | ||
Neuromodulation($M)2 | 341 | 318 | 333 | 293 | 303 | 271 | 299 | 268 | 282 | 256 | 268 | ||
United States($M) | 257 | 236 | 253 | 230 | 228 | 204 | 231 | 211 | 214 | 190 | 206 | ||
Int'l($M) | 84 | 82 | 80 | 63 | 75 | 67 | 68 | 57 | 68 | 66 | 63 | ||
Interventional Oncology & Embolization($M)2 | 283 | 268 | 251 | 228 | |||||||||
United States($M) | 175 | 170 | 155 | 142 | |||||||||
Int'l($M) | 108 | 99 | 96 | 87 | |||||||||
United States($M) | 3,426 | 3,284 | 3,385 | 3,294 | 3,224 | 2,960 | 2,893 | 2,593 | 2,466 | 2,258 | 2,213 | ||
Int'l($M) | 2,017 | 1,920 | 1,901 | 1,770 | 1,837 | 1,702 | 1,669 | 1,616 | 1,654 | 1,599 | 1,513 | ||
Emerging Markets($M) | 771 | 765 | 758 | 690 | 668 | 684 | 680 | 648 | 595 | ||||
Cardiovascular($M) | 1,197 | 1,125 | 1,050 | 1,135 | 1,079 | 1,068 | 912 | 862 | 782 | 674 | |||
MedSurg($M) | 598 | 533 | 575 | 566 | 606 | 536 | 563 | 518 | 522 | 485 | |||
Cardiovascular Segment — Worldwide Net Sales ($M)($M)7 | 3,406 | 3,624 | 3,503 | 3,477 | 3,343 | 3,345 | 3,085 | 2,942 | 2,731 | 2,637 | 2,445 | 2,285 | |
Cardiovascular Segment — Organic Net Sales Growth (%)(%) | 1.9% | 7.8% | 11.2% | 16.1% | 19.4% | 23.2% | 25.6% | 27.4% | 24.6% | 19.0% | 16.3% | 13.3% | |
Cardiovascular Segment — Operational (Constant Currency) Growth (%)(%) | 1.9% | 7.8% | 11.2% | 16.5% | 21.5% | 25.5% | 27.6% | 29.5% | 25.1% | 19.7% | 17.4% | 13.8% | |
Cardiovascular Segment — Reported Net Sales Growth (%)(%) | 1.9% | 8.3% | 13.5% | 18.2% | 22.4% | 26.8% | 26.2% | 28.8% | 25.0% | 17.8% | 15.9% | 13.9% | |
Cardiovascular Segment — Foreign Currency Impact (%)(%) | 0.0% | -0.6% | -2.3% | -1.7% | -1.0% | -1.3% | 1.4% | 0.8% | 0.1% | 1.9% | 1.6% | -0.2% | |
Cardiovascular Segment — Acquisitions & Divestitures Impact (%)(%) | 0.0% | 0.0% | 0.0% | -0.4% | -2.1% | -2.3% | -2.0% | -2.2% | -0.4% | -0.7% | -1.1% | -0.5% | |
Cardiovascular Segment — U.S. Net Sales ($M)($M)2 | 2,095 | 2,175 | 2,137 | 2,147 | 2,092 | 2,042 | 1,868 | 1,779 | 1,586 | 1,474 | 1,316 | 1,251 | |
Cardiovascular U.S. — Operational Sales Growth (%)(%) | 0.2% | 6.5% | 14.4% | 20.7% | 31.9% | 38.5% | 41.9% | ||||||
Cardiovascular U.S. — Reported Sales Growth (%)(%) | 0.2% | 6.5% | 14.4% | 20.7% | 31.9% | 38.5% | 41.9% | ||||||
Cardiovascular Segment — International Net Sales ($M)($M)3 | 1,311 | 1,449 | 1,366 | 1,329 | 1,251 | 1,303 | 1,218 | 1,163 | 1,145 | 1,163 | 1,129 | 1,034 | |
Cardiovascular International — Operational Sales Growth (%)(%) | 4.7% | 9.8% | 6.3% | 10.0% | 7.0% | 9.0% | 10.9% | ||||||
Cardiovascular International — Reported Sales Growth (%)(%) | 4.8% | 11.2% | 12.2% | 14.3% | 9.3% | 12.1% | 7.9% | ||||||
Cardiovascular International — Foreign Currency Impact (%)(%) | -0.1% | -1.5% | -5.8% | -4.3% | -2.3% | -3.1% | 3.0% | ||||||
Interventional Cardiology & Vascular Therapies (ICVT) — Worldwide Net Sales ($M)($M)9 | 1,273 | 1,333 | 1,244 | 1,202 | 1,135 | 1,178 | 1,124 | 1,091 | 1,047 | 1,040 | 1,021 | ||
Interventional Cardiology & Vascular Therapies (ICVT) — Organic Net Sales Growth (%)(%) | 11.9% | 12.1% | 7.8% | 8.3% | 3.1% | 6.8% | 7.2% | ||||||
Interventional Cardiology & Vascular Therapies (ICVT) — Operational (Constant Currency) Net Sales Growth (%)(%) | 11.9% | 12.1% | 7.8% | 8.3% | 7.4% | 11.9% | 12.0% | ||||||
Interventional Cardiology & Vascular Therapies (ICVT) — Reported Net Sales Growth (%)(%) | 12.1% | 13.1% | 10.7% | 10.2% | 8.3% | 13.3% | 10.1% | ||||||
Interventional Cardiology & Vascular Therapies (ICVT) — Foreign Currency Impact on Growth (%)(%) | -0.2% | -1.0% | -2.9% | -1.9% | -0.9% | -1.4% | 1.9% | ||||||
Interventional Cardiology & Vascular Therapies (ICVT) — Acquisitions & Divestitures Impact on Growth (%)(%) | 0.0% | 0.0% | 0.0% | 0.0% | -4.4% | -5.1% | -4.7% | ||||||
Interventional Cardiology & Vascular Therapies (ICVT) — U.S. Net Sales ($M)($M)2 | 578 | 586 | 552 | 537 | 504 | 499 | 467 | 459 | 397 | 379 | 372 | ||
Interventional Cardiology & Vascular Therapies (ICVT) U.S. — Operational Sales Growth (%)(%) | 14.6% | 17.5% | 18.3% | 17.1% | 26.8% | 31.6% | 25.5% | ||||||
Interventional Cardiology & Vascular Therapies (ICVT) U.S. — Reported Sales Growth (%)(%) | 14.6% | 17.5% | 18.3% | 17.1% | 26.8% | 31.6% | 25.5% | ||||||
Interventional Cardiology & Vascular Therapies (ICVT) — International Net Sales ($M)($M)3 | 695 | 746 | 692 | 665 | 631 | 679 | 657 | 632 | 650 | 661 | 649 | ||
Interventional Cardiology & Vascular Therapies (ICVT) International — Operational Sales Growth (%)(%) | 9.7% | 8.2% | 0.4% | 1.9% | -4.4% | 0.6% | 4.2% | ||||||
Interventional Cardiology & Vascular Therapies (ICVT) International — Reported Sales Growth (%)(%) | 10.2% | 9.9% | 5.2% | 5.2% | -3.0% | 2.8% | 1.3% | ||||||
Interventional Cardiology & Vascular Therapies (ICVT) International — Foreign Currency Impact (%)(%) | -0.4% | -1.7% | -4.9% | -3.3% | -1.5% | -2.2% | 3.0% | ||||||
Interventional Cardiology (Standalone Sub-Unit) — Worldwide Net Sales ($M)($M)5 | 818 | 849 | 778 | ||||||||||
Interventional Cardiology — Constant-Currency Net Sales ($M)($M) | 816 | 840 | 756 | ||||||||||
Interventional Cardiology — Organic Net Sales Growth (%)(%) | 19.0% | 14.9% | 8.5% | 10.0% | |||||||||
Interventional Cardiology — Operational Net Sales Growth (%)(%) | 19.0% | 14.9% | 8.5% | 10.0% | |||||||||
Interventional Cardiology — Reported Net Sales Growth (%)(%) | 19.3% | 16.1% | 11.7% | 12.0% | |||||||||
Interventional Cardiology — Foreign Currency Impact (%)(%) | -0.3% | -1.1% | -3.1% | -2.0% | |||||||||
Vascular Therapies / Peripheral Vascular (Standalone Sub-Unit) — Worldwide Net Sales ($M)($M)6 | 454 | 484 | 466 | ||||||||||
Vascular Therapies — Constant-Currency Net Sales ($M)($M) | 454 | 481 | 456 | ||||||||||
Vascular Therapies — Organic Net Sales Growth (%)(%) | 1.0% | 7.6% | 6.6% | 6.0% | |||||||||
Vascular Therapies — Operational Net Sales Growth (%)(%) | 1.0% | 7.6% | 6.6% | 6.0% | |||||||||
Vascular Therapies — Reported Net Sales Growth (%)(%) | 1.2% | 8.4% | 9.1% | 7.0% | |||||||||
Vascular Therapies — Foreign Currency Impact (%)(%) | -0.2% | -0.8% | -2.4% | -1.0% | |||||||||
Vascular Therapies — Acquisitions Impact (%)(%) | 0.0% | 0.0% | 0.0% | 0.0% | |||||||||
Watchman (Left Atrial Appendage Closure — LAAC) — Worldwide Net Sales ($M)($M)7 | 482 | 507 | 506 | 535 | 512 | 486 | 425 | 413 | 380 | 379 | 344 | 345 | |
Watchman (Left Atrial Appendage Closure — LAAC) — Organic Net Sales Growth (%)(%) | -5.9% | 4.2% | 18.8% | 29.0% | 34.6% | 28.0% | 23.7% | 20.0% | 17.8% | 20.0% | 18.8% | 22.9% | |
Watchman (Left Atrial Appendage Closure — LAAC) — Operational (Constant Currency) Net Sales Growth (%)(%) | -5.9% | 4.2% | 18.8% | 29.0% | 34.6% | 28.0% | 23.7% | 20.0% | 17.8% | 20.0% | 18.8% | 22.9% | |
Watchman (Left Atrial Appendage Closure — LAAC) — Reported Net Sales Growth (%)(%) | -5.8% | 4.3% | 19.2% | 29.4% | 34.8% | 28.4% | 23.4% | 19.9% | 17.8% | 19.6% | 18.5% | 22.9% | |
Watchman (Left Atrial Appendage Closure — LAAC) — Foreign Currency Impact on Growth (%)(%) | -0.1% | -0.1% | -0.4% | -0.4% | -0.2% | -0.3% | 0.2% | 0.1% | 0.0% | 0.5% | 0.4% | 0.0% | |
Watchman (Left Atrial Appendage Closure — LAAC) — Acquisitions & Divestitures Impact on Growth (%)(%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
Watchman (Left Atrial Appendage Closure — LAAC) — U.S. Net Sales ($M)($M)2 | 438 | 459 | 462 | 485 | 470 | 446 | 390 | 376 | 342 | 342 | 311 | 312 | |
Watchman (Left Atrial Appendage Closure — LAAC) U.S. — Operational Sales Growth (%)(%) | -6.8% | 3.0% | 18.3% | 29.1% | 37.2% | 30.2% | 25.6% | 20.4% | 17.5% | 19.5% | 17.1% | 23.0% | |
Watchman (Left Atrial Appendage Closure — LAAC) U.S. — Reported Sales Growth (%)(%) | -6.8% | 3.0% | 18.3% | 29.1% | 37.2% | 30.2% | 25.6% | 20.4% | 17.5% | 19.5% | 17.1% | 23.0% | |
Watchman (Left Atrial Appendage Closure — LAAC) — International Net Sales ($M)($M)3 | 45 | 48 | 44 | 50 | 43 | 40 | 34 | 38 | 38 | 36 | 33 | 33 | |
Watchman (Left Atrial Appendage Closure — LAAC) International — Operational Sales Growth (%)(%) | 4.0% | 17.7% | 23.7% | 27.7% | 10.8% | 7.8% | 5.5% | 16.7% | 20.5% | 25.0% | 36.8% | 21.7% | |
Watchman (Left Atrial Appendage Closure — LAAC) International — Reported Sales Growth (%)(%) | 4.9% | 19.3% | 29.2% | 31.8% | 12.7% | 11.4% | 3.1% | 15.4% | 20.9% | 20.3% | 32.4% | 21.7% | |
Watchman (Left Atrial Appendage Closure — LAAC) International — Foreign Currency Impact (%)(%) | -0.9% | -1.5% | -5.5% | -4.2% | -1.9% | -3.7% | 2.3% | 1.3% | -0.4% | 4.7% | 4.4% | 0.0% | |
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) — Worldwide Net Sales ($M)($M)7 | 816 | 916 | 905 | 890 | 865 | 840 | 730 | 649 | 527 | 428 | 300 | 240 | |
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) — Organic Net Sales Growth (%)(%) | -5.3% | 9.1% | 21.7% | 35.1% | 62.8% | 93.7% | 145.0% | 171.8% | 176.7% | 124.6% | 71.7% | 43.1% | |
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) — Operational (Constant Currency) Net Sales Growth (%)(%) | -5.3% | 9.1% | 21.7% | 35.1% | 62.8% | 93.7% | 145.0% | 171.8% | 176.7% | 124.6% | 71.7% | 43.1% | |
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) — Reported Net Sales Growth (%)(%) | -5.7% | 9.1% | 23.9% | 37.1% | 64.2% | 96.1% | 143.2% | 170.6% | 177.0% | 121.9% | 70.0% | 43.9% | |
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) — Foreign Currency Impact on Growth (%)(%) | 0.4% | 0.0% | -2.3% | -1.9% | -1.4% | -2.4% | 1.8% | 1.2% | -0.3% | 2.7% | 1.7% | -0.8% | |
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) — Acquisitions & Divestitures Impact on Growth (%)(%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) — U.S. Net Sales ($M)($M)2 | 556 | 606 | 603 | 606 | 607 | 587 | 511 | 461 | 366 | 271 | 158 | 110 | |
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) U.S. — Operational Sales Growth (%)(%) | -8.4% | 3.1% | 18.0% | 31.3% | 65.8% | 116.8% | 224.5% | 317.8% | 312.2% | 218.0% | 84.8% | 40.4% | |
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) U.S. — Reported Sales Growth (%)(%) | -8.4% | 3.1% | 18.0% | 31.3% | 65.8% | 116.8% | 224.5% | 317.8% | 312.2% | 218.0% | 84.8% | 40.4% | |
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) — International Net Sales ($M)($M)3 | 259 | 310 | 302 | 285 | 258 | 252 | 219 | 188 | 160 | 157 | 143 | 130 | |
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) International — Operational Sales Growth (%)(%) | 1.9% | 23.1% | 30.1% | 44.6% | 56.1% | 53.9% | 57.3% | 47.4% | 57.8% | 50.7% | 59.5% | 45.5% | |
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) International — Reported Sales Growth (%)(%) | 0.7% | 22.9% | 37.8% | 51.3% | 60.7% | 60.5% | 53.5% | 45.2% | 58.3% | 45.9% | 56.1% | 47.0% | |
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) International — Foreign Currency Impact (%)(%) | 1.2% | 0.2% | -7.6% | -6.7% | -4.6% | -6.6% | 3.8% | 2.2% | -0.5% | 4.9% | 3.3% | -1.5% | |
Cardiac Rhythm Management (CRM) — Worldwide Net Sales ($M)($M)7 | 568 | 585 | 578 | 587 | 578 | 590 | 578 | 566 | 561 | 576 | 575 | 553 | |
Cardiac Rhythm Management (CRM) — Organic Net Sales Growth (%)(%) | -1.6% | -1.6% | -2.5% | 1.4% | 1.8% | 1.1% | 1.4% | 2.9% | 1.7% | 2.9% | 5.3% | 5.4% | |
Cardiac Rhythm Management (CRM) — Operational (Constant Currency) Net Sales Growth (%)(%) | -1.6% | -1.6% | -2.5% | 1.4% | 1.8% | 1.1% | 1.4% | 2.9% | 1.7% | 2.9% | 5.3% | 5.4% | |
Cardiac Rhythm Management (CRM) — Reported Net Sales Growth (%)(%) | -1.6% | -0.9% | 0.1% | 3.6% | 3.0% | 2.4% | 0.4% | 2.5% | 1.8% | 1.9% | 5.0% | 6.2% | |
Cardiac Rhythm Management (CRM) — Foreign Currency Impact on Growth (%)(%) | 0.1% | -0.8% | -2.7% | -2.2% | -1.2% | -1.3% | 1.0% | 0.4% | -0.1% | 1.1% | 0.3% | -0.8% | |
Cardiac Rhythm Management (CRM) — Acquisitions & Divestitures Impact on Growth (%)(%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
Cardiac Rhythm Management (CRM) — U.S. Net Sales ($M)($M)2 | 349 | 349 | 349 | 359 | 354 | 355 | 358 | 349 | 349 | 352 | 354 | 349 | |
Cardiac Rhythm Management (CRM) U.S. — Operational Sales Growth (%)(%) | -1.4% | -1.7% | -2.4% | 2.8% | 1.5% | 1.0% | 1.0% | 0.1% | -1.7% | -1.3% | 2.5% | 5.1% | |
Cardiac Rhythm Management (CRM) U.S. — Reported Sales Growth (%)(%) | -1.4% | -1.7% | -2.4% | 2.8% | 1.5% | 1.0% | 1.0% | 0.1% | -1.7% | -1.3% | 2.5% | 5.1% | |
Cardiac Rhythm Management (CRM) — International Net Sales ($M)($M)3 | 220 | 236 | 229 | 228 | 224 | 235 | 220 | 218 | 213 | 224 | 221 | 204 | |
Cardiac Rhythm Management (CRM) International — Operational Sales Growth (%)(%) | -1.8% | -1.6% | -2.8% | -0.9% | 2.2% | 1.3% | 2.1% | 7.7% | 7.9% | 10.1% | 10.1% | 5.9% | |
Cardiac Rhythm Management (CRM) International — Reported Sales Growth (%)(%) | -2.0% | 0.3% | 4.1% | 4.8% | 5.4% | 4.8% | -0.6% | 6.5% | 8.1% | 7.3% | 9.2% | 8.2% | |
Cardiac Rhythm Management (CRM) International — Foreign Currency Impact (%)(%) | 0.2% | -1.9% | -7.0% | -5.7% | -3.2% | -3.4% | 2.7% | 1.1% | -0.2% | 2.8% | 0.9% | -2.2% | |
Interventional Oncology & Embolization (IO&E) — Worldwide Net Sales ($M)($M)7 | 267 | 283 | 268 | 263 | 253 | 251 | 228 | 222 | 215 | 214 | 204 | ||
Interventional Oncology & Embolization (IO&E) — Organic Net Sales Growth (%)(%) | 4.8% | 11.8% | 15.2% | 12.2% | 11.5% | 13.2% | 13.1% | ||||||
Interventional Oncology & Embolization (IO&E) — Operational (Constant Currency) Net Sales Growth (%)(%) | 4.8% | 11.8% | 15.2% | 17.3% | 16.9% | 16.2% | 13.1% | ||||||
Interventional Oncology & Embolization (IO&E) — Reported Net Sales Growth (%)(%) | 5.2% | 12.9% | 17.5% | 18.6% | 17.6% | 17.0% | 12.0% | ||||||
Interventional Oncology & Embolization (IO&E) — Foreign Currency Impact on Growth (%)(%) | -0.4% | -1.1% | -2.3% | -1.3% | -0.7% | -0.8% | 1.1% | ||||||
Interventional Oncology & Embolization (IO&E) — Acquisitions & Divestitures Impact on Growth (%)(%) | 0.0% | 0.0% | 0.0% | -5.1% | -5.4% | -3.0% | 0.0% | ||||||
Interventional Oncology & Embolization (IO&E) — U.S. Net Sales ($M)($M)2 | 175 | 175 | 170 | 161 | 157 | 155 | 142 | 135 | 131 | 130 | 122 | ||
Interventional Oncology & Embolization (IO&E) U.S. — Operational Sales Growth (%)(%) | 10.9% | 12.8% | 19.8% | 19.5% | 20.1% | 18.8% | 16.1% | ||||||
Interventional Oncology & Embolization (IO&E) U.S. — Reported Sales Growth (%)(%) | 10.9% | 12.8% | 19.8% | 19.5% | 20.1% | 18.8% | 16.1% | ||||||
Interventional Oncology & Embolization (IO&E) — International Net Sales ($M)($M)3 | 92 | 108 | 99 | 102 | 96 | 96 | 87 | 87 | 84 | 84 | 82 | ||
Interventional Oncology & Embolization (IO&E) International — Operational Sales Growth (%)(%) | -5.2% | 10.0% | 7.8% | 13.7% | 11.9% | 12.0% | 8.7% | ||||||
Interventional Oncology & Embolization (IO&E) International — Reported Sales Growth (%)(%) | -4.0% | 12.9% | 13.7% | 17.2% | 13.6% | 14.1% | 5.9% | ||||||
Interventional Oncology & Embolization (IO&E) International — Foreign Currency Impact (%)(%) | -1.2% | -2.9% | -5.9% | -3.4% | -1.8% | -2.0% | 2.8% | ||||||
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) — Worldwide Net Sales ($M)($M)7 | 686 | 731 | 697 | 668 | 661 | 665 | 652 | 614 | |||||
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) — Organic Net Sales Growth (%)(%) | 2.9% | 8.6% | 9.0% | 10.1% | 13.8% | 8.7% | 13.1% | 9.5% | |||||
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) — Operational (Constant Currency) Net Sales Growth (%)(%) | 2.9% | 8.6% | 9.0% | 10.1% | 13.8% | 8.7% | 13.1% | 9.5% | |||||
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) — Reported Net Sales Growth (%)(%) | 3.7% | 10.0% | 6.9% | 8.8% | 13.4% | 5.7% | 10.3% | 9.3% | |||||
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) — Foreign Currency Impact on Growth (%)(%) | -0.9% | -1.4% | 2.1% | 1.3% | 0.5% | 3.0% | 2.8% | 0.2% | |||||
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) — Acquisitions & Divestitures Impact on Growth (%)(%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |||||
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) — U.S. Net Sales ($M)($M)2 | 256 | 252 | 232 | 217 | 212 | 201 | 195 | 188 | |||||
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) U.S. — Operational Sales Growth (%)(%) | 20.9% | 25.4% | 19.1% | 15.2% | 16.2% | 6.4% | 6.3% | 7.1% | |||||
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) U.S. — Reported Sales Growth (%)(%) | 20.9% | 25.4% | 19.1% | 15.2% | 16.2% | 6.4% | 6.3% | 7.1% | |||||
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) — International Net Sales ($M)($M)3 | 429 | 479 | 465 | 451 | 449 | 464 | 457 | 426 | |||||
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) International — Operational Sales Growth (%)(%) | -5.6% | 1.4% | 4.6% | 7.8% | 12.7% | 9.7% | 16.1% | 10.6% | |||||
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) International — Reported Sales Growth (%)(%) | -4.3% | 3.4% | 1.7% | 5.9% | 12.1% | 5.3% | 12.1% | 10.3% | |||||
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) International — Foreign Currency Impact (%)(%) | -1.3% | -2.0% | 3.0% | 1.9% | 0.7% | 4.3% | 4.1% | 0.3% | |||||
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) — Worldwide Net Sales ($M)($M)7 | 2,641 | 2,647 | 2,429 | 2,297 | 2,129 | 2,047 | 1,872 | 1,751 | |||||
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) — Organic Net Sales Growth (%)(%) | 23.1% | 27.9% | 31.2% | 31.9% | 29.3% | 22.0% | 17.9% | 14.2% | |||||
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) — Operational (Constant Currency) Net Sales Growth (%)(%) | 23.1% | 27.9% | 31.2% | 31.9% | 29.3% | 22.0% | 17.9% | 14.2% | |||||
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) — Reported Net Sales Growth (%)(%) | 24.0% | 29.3% | 29.8% | 31.1% | 29.2% | 20.1% | 16.5% | 14.5% | |||||
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) — Foreign Currency Impact on Growth (%)(%) | -1.0% | -1.4% | 1.4% | 0.8% | 0.1% | 1.9% | 1.4% | -0.3% | |||||
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) — Acquisitions & Divestitures Impact on Growth (%)(%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |||||
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) — U.S. Net Sales ($M)($M)2 | 1,687 | 1,640 | 1,491 | 1,402 | 1,269 | 1,166 | 1,017 | 959 | |||||
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) U.S. — Operational Sales Growth (%)(%) | 32.9% | 40.7% | 46.6% | 46.2% | 38.3% | 27.2% | 15.7% | 14.2% | |||||
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) U.S. — Reported Sales Growth (%)(%) | 32.9% | 40.7% | 46.6% | 46.2% | 38.3% | 27.2% | 15.7% | 14.2% | |||||
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) — International Net Sales ($M)($M)3 | 954 | 1,007 | 938 | 894 | 859 | 881 | 854 | 792 | |||||
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) International — Operational Sales Growth (%)(%) | 8.6% | 11.0% | 12.8% | 14.6% | 18.0% | 16.0% | 20.6% | 14.2% | |||||
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) International — Reported Sales Growth (%)(%) | 11.0% | 14.3% | 9.8% | 12.9% | 17.8% | 12.0% | 17.5% | 14.9% | |||||
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) International — Foreign Currency Impact (%)(%) | -2.4% | -3.3% | 3.0% | 1.7% | 0.2% | 4.0% | 3.1% | -0.6% | |||||
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) — Worldwide Net Sales ($M)($M)7 | 702 | 698 | 656 | 645 | 602 | 590 | 573 | 533 | |||||
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) — Organic Net Sales Growth (%)(%) | 6.3% | 7.0% | 7.4% | 12.5% | 10.3% | 9.4% | 11.3% | 10.2% | |||||
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) — Operational (Constant Currency) Net Sales Growth (%)(%) | 15.8% | 17.1% | 15.8% | 21.7% | 12.0% | 12.3% | 16.0% | 12.2% | |||||
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) — Reported Net Sales Growth (%)(%) | 16.7% | 18.3% | 14.4% | 21.0% | 11.8% | 10.2% | 13.9% | 12.1% | |||||
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) — Foreign Currency Impact on Growth (%)(%) | -0.9% | -1.1% | 1.4% | 0.8% | 0.1% | 2.1% | 2.1% | 0.1% | |||||
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) — Acquisitions & Divestitures Impact on Growth (%)(%) | -9.5% | -10.2% | -8.4% | -9.2% | -1.7% | -2.8% | -4.6% | -2.1% | |||||
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) — U.S. Net Sales ($M)($M)2 | 405 | 402 | 376 | 377 | 316 | 308 | 299 | 292 | |||||
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) U.S. — Operational Sales Growth (%)(%) | 28.1% | 30.3% | 25.7% | 29.2% | 11.6% | 8.0% | 9.0% | 9.6% | |||||
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) U.S. — Reported Sales Growth (%)(%) | 28.1% | 30.3% | 25.7% | 29.2% | 11.6% | 8.0% | 9.0% | 9.6% | |||||
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) — International Net Sales ($M)($M)3 | 297 | 296 | 280 | 268 | 285 | 281 | 274 | 242 | |||||
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) International — Operational Sales Growth (%)(%) | 2.2% | 2.8% | 4.9% | 12.7% | 12.4% | 17.2% | 24.4% | 15.6% | |||||
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) International — Reported Sales Growth (%)(%) | 4.1% | 5.2% | 2.0% | 11.0% | 12.1% | 12.7% | 19.8% | 15.3% | |||||
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) International — Foreign Currency Impact (%)(%) | -1.9% | -2.4% | 2.9% | 1.7% | 0.3% | 4.5% | 4.5% | 0.3% | |||||
MedSurg Segment — Worldwide Net Sales ($M)($M)5 | 1,733 | 1,818 | 1,701 | 1,809 | 1,722 | 1,716 | 1,577 | 1,619 | 1,479 | 1,483 | 1,412 | 1,441 | |
MedSurg Segment — Organic Net Sales Growth (%)(%) | 0.7% | 5.4% | 5.7% | 6.5% | 7.6% | 7.0% | 5.3% | 7.0% | 7.7% | 7.6% | 7.8% | 8.9% | |
MedSurg Segment — Operational (Constant Currency) Growth (%)(%) | 0.7% | 5.4% | 5.7% | 10.2% | 15.6% | 14.7% | 12.8% | 13.0% | 10.4% | 10.1% | 10.9% | 10.5% | |
MedSurg Segment — Reported Net Sales Growth (%)(%) | 0.6% | 5.9% | 7.8% | 11.7% | 16.4% | 15.7% | 11.7% | 12.4% | 10.3% | 9.0% | 10.3% | 11.1% | |
MedSurg Segment — Foreign Currency Impact (%)(%) | 0.1% | -0.5% | -2.1% | -1.5% | -0.8% | -1.0% | 1.1% | 0.6% | 0.1% | 1.0% | 0.6% | -0.6% | |
MedSurg Segment — Acquisitions & Divestitures Impact (%)(%) | 0.0% | 0.0% | 0.0% | -3.7% | -8.0% | -7.7% | -7.5% | -6.0% | -2.7% | -2.5% | -3.1% | -1.6% | |
Endoscopy — Worldwide Net Sales ($M)($M)7 | 741 | 793 | 736 | 760 | 747 | 737 | 673 | 690 | 678 | 676 | 642 | 645 | |
Endoscopy — Organic Net Sales Growth (%)(%) | -0.6% | 7.0% | 6.8% | 8.2% | 9.0% | 7.8% | 5.5% | 7.0% | 7.4% | 7.9% | 9.8% | 10.8% | |
Endoscopy — Operational (Constant Currency) Net Sales Growth (%)(%) | -0.6% | 7.0% | 6.8% | 8.2% | 9.0% | 7.8% | 5.9% | 7.6% | 7.9% | 8.4% | 12.1% | 12.2% | |
Endoscopy — Reported Net Sales Growth (%)(%) | -0.8% | 7.6% | 9.4% | 10.1% | 10.1% | 9.1% | 4.7% | 7.0% | 7.8% | 7.1% | 11.4% | 12.9% | |
Endoscopy — Foreign Currency Impact on Growth (%)(%) | 0.1% | -0.7% | -2.6% | -1.9% | -1.1% | -1.3% | 1.2% | 0.6% | 0.1% | 1.3% | 0.7% | -0.7% | |
Endoscopy — Acquisitions & Divestitures Impact on Growth (%)(%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -0.4% | -0.7% | -0.5% | -0.5% | -2.3% | -1.4% | |
Endoscopy — U.S. Net Sales ($M)($M)2 | 468 | 491 | 446 | 464 | 462 | 456 | 420 | 423 | 417 | 415 | 395 | 394 | |
Endoscopy U.S. — Operational Sales Growth (%)(%) | 1.2% | 7.6% | 6.2% | 9.5% | 10.8% | 10.0% | 6.3% | 7.5% | 9.1% | 8.0% | 12.6% | 12.9% | |
Endoscopy U.S. — Reported Sales Growth (%)(%) | 1.2% | 7.6% | 6.2% | 9.5% | 10.8% | 10.0% | 6.3% | 7.5% | 9.1% | 8.0% | 12.6% | 12.9% | |
Endoscopy — International Net Sales ($M)($M)3 | 274 | 303 | 290 | 296 | 285 | 281 | 253 | 267 | 261 | 261 | 247 | 252 | |
Endoscopy International — Operational Sales Growth (%)(%) | -3.6% | 6.0% | 7.7% | 6.0% | 6.3% | 4.3% | 5.4% | 7.8% | 6.0% | 9.1% | 11.4% | 11.2% | |
Endoscopy International — Reported Sales Growth (%)(%) | -4.0% | 7.7% | 14.8% | 10.9% | 9.2% | 7.6% | 2.2% | 6.2% | 5.8% | 5.9% | 9.6% | 13.0% | |
Endoscopy International — Foreign Currency Impact (%)(%) | 0.4% | -1.7% | -7.0% | -4.9% | -2.9% | -3.3% | 3.2% | 1.6% | 0.2% | 3.3% | 1.8% | -1.8% | |
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) — Worldwide Net Sales ($M)($M)7 | 661 | 684 | 646 | 717 | 682 | 676 | 633 | 630 | 532 | 525 | 513 | 527 | |
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) — Organic Net Sales Growth (%)(%) | -3.1% | 0.8% | 0.5% | 3.2% | 5.4% | 6.3% | 4.4% | 7.9% | 10.4% | 9.1% | 9.8% | 9.9% | |
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) — Operational (Constant Currency) Net Sales Growth (%)(%) | -3.1% | 0.8% | 0.5% | 12.7% | 27.5% | 28.0% | 24.5% | 20.1% | 10.4% | 9.1% | 9.8% | 9.9% | |
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) — Reported Net Sales Growth (%)(%) | -3.2% | 1.1% | 2.1% | 13.8% | 28.1% | 28.9% | 23.5% | 19.5% | 10.3% | 8.2% | 9.3% | 10.5% | |
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) — Foreign Currency Impact on Growth (%)(%) | 0.1% | -0.3% | -1.6% | -1.1% | -0.6% | -0.8% | 1.0% | 0.5% | 0.1% | 0.9% | 0.5% | -0.5% | |
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) — Acquisitions & Divestitures Impact on Growth (%)(%) | 0.0% | 0.0% | 0.0% | -9.5% | -22.1% | -21.7% | -20.1% | -12.2% | 0.0% | 0.0% | 0.0% | 0.0% | |
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) — U.S. Net Sales ($M)($M)2 | 492 | 503 | 465 | 522 | 511 | 499 | 469 | 459 | 379 | 363 | 356 | 362 | |
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) U.S. — Operational Sales Growth (%)(%) | -3.8% | 0.8% | -0.8% | 13.7% | 34.8% | 37.4% | 31.8% | 26.7% | 11.1% | 6.8% | 9.1% | 7.9% | |
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) U.S. — Reported Sales Growth (%)(%) | -3.8% | 0.8% | -0.8% | 13.7% | 34.8% | 37.4% | 31.8% | 26.7% | 11.1% | 6.8% | 9.1% | 7.9% | |
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) — International Net Sales ($M)($M)3 | 169 | 181 | 182 | 195 | 171 | 178 | 165 | 171 | 153 | 162 | 157 | 165 | |
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) International — Operational Sales Growth (%)(%) | -1.2% | 0.7% | 4.3% | 9.9% | 9.5% | 7.0% | 8.1% | 5.5% | 8.9% | 14.4% | 11.5% | 14.8% | |
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) International — Reported Sales Growth (%)(%) | -1.4% | 1.9% | 10.3% | 14.1% | 11.7% | 9.7% | 4.8% | 3.8% | 8.4% | 11.3% | 9.9% | 16.7% | |
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) International — Foreign Currency Impact (%)(%) | 0.2% | -1.2% | -6.1% | -4.2% | -2.2% | -2.7% | 3.4% | 1.7% | 0.5% | 3.2% | 1.6% | -1.9% | |
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) — Worldwide Net Sales ($M)($M)7 | 331 | 341 | 318 | 332 | 293 | 303 | 271 | 299 | 268 | 282 | 256 | 269 | |
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) — Organic Net Sales Growth (%)(%) | 13.0% | 12.2% | 15.4% | 9.9% | 8.6% | 6.6% | 6.8% | 5.5% | 2.7% | 3.7% | -1.3% | 2.6% | |
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) — Operational (Constant Currency) Net Sales Growth (%)(%) | 13.0% | 12.2% | 15.4% | 9.9% | 8.6% | 6.6% | 6.8% | 11.9% | 17.1% | 16.2% | 9.8% | 7.5% | |
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) — Reported Net Sales Growth (%)(%) | 13.1% | 12.7% | 17.4% | 11.1% | 9.1% | 7.2% | 5.8% | 11.4% | 17.0% | 15.5% | 9.5% | 8.0% | |
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) — Foreign Currency Impact on Growth (%)(%) | -0.1% | -0.6% | -1.9% | -1.2% | -0.5% | -0.6% | 0.9% | 0.5% | 0.1% | 0.7% | 0.3% | -0.5% | |
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) — Acquisitions & Divestitures Impact on Growth (%)(%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -6.4% | -14.4% | -12.5% | -11.2% | -4.9% | |
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) — U.S. Net Sales ($M)($M)2 | 255 | 257 | 236 | 252 | 230 | 228 | 204 | 231 | 211 | 214 | 190 | 206 | |
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) U.S. — Operational Sales Growth (%)(%) | 11.1% | 13.1% | 15.7% | 9.2% | 8.8% | 6.3% | 7.2% | 12.2% | 20.9% | 16.8% | 10.5% | 5.2% | |
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) U.S. — Reported Sales Growth (%)(%) | 11.1% | 13.1% | 15.7% | 9.2% | 8.8% | 6.3% | 7.2% | 12.2% | 20.9% | 16.8% | 10.5% | 5.2% | |
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) — International Net Sales ($M)($M)3 | 76 | 84 | 82 | 80 | 63 | 75 | 67 | 68 | 57 | 68 | 66 | 63 | |
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) International — Operational Sales Growth (%)(%) | 19.9% | 9.4% | 14.7% | 12.2% | 8.0% | 7.4% | 5.4% | 11.2% | 5.1% | 14.1% | 8.1% | 16.0% | |
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) International — Reported Sales Growth (%)(%) | 20.4% | 11.8% | 22.5% | 17.6% | 10.3% | 9.9% | 1.9% | 9.1% | 4.6% | 11.4% | 6.9% | 18.5% | |
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) International — Foreign Currency Impact (%)(%) | -0.5% | -2.4% | -7.8% | -5.4% | -2.3% | -2.6% | 3.6% | 2.2% | 0.6% | 2.7% | 1.1% | -2.5% | |
Consolidated Total Company — Worldwide Net Sales ($M)($M)5 | 5,138 | 5,442 | 5,203 | 5,286 | 5,065 | 5,061 | 4,663 | 4,561 | 4,209 | 4,120 | 3,856 | 3,725 | |
Consolidated Total Company — Organic Net Sales Growth (%)(%) | 1.5% | 7.0% | 9.4% | 12.7% | 15.3% | 17.4% | 18.2% | 19.5% | 18.2% | 14.7% | 13.1% | 13.6% | |
Consolidated Total Company — Operational (Constant Currency) Net Sales Growth (%)(%) | 1.5% | 7.0% | 9.4% | 14.3% | 19.4% | 21.6% | 22.2% | 23.1% | 19.5% | 16.1% | 15.0% | 14.5% | |
Consolidated Total Company — Reported Net Sales Growth (%)(%) | 1.5% | 7.5% | 11.6% | 15.9% | 20.3% | 22.8% | 20.9% | 22.4% | 19.4% | 14.5% | 13.8% | 14.9% | |
Consolidated Total Company — Foreign Currency Impact on Growth (%)(%) | 0.0% | -0.5% | -2.2% | -1.6% | -0.9% | -1.2% | 1.3% | 0.7% | 0.1% | 1.6% | 1.2% | -0.4% | |
Consolidated Total Company — Acquisitions & Divestitures Impact on Growth (%)(%) | 0.0% | 0.0% | 0.0% | -1.6% | -4.2% | -4.2% | -4.0% | -3.6% | -1.3% | -1.4% | -1.9% | -0.9% | |
Cardiovascular — Segment Operating Income ($M)($M)6 | 1,016 | 1,197 | 1,125 | 1,010 | 1,145 | 1,079 | 1,068 | 912 | 862 | 782 | 674 | 641 | |
Cardiovascular — Segment Operating Margin (%)(%) | 29.8% | 33.1% | 32.1% | 34.2% | 32.1% | 33.8% | 31.5% | 29.4% | 27.4% | ||||
Cardiovascular — Adjusted Segment Operating Margin (%)(%) | 29.8% | 33.1% | 32.1% | 30.3% | 34.2% | 32.1% | 33.8% | 30.6% | 31.5% | 28.9% | 26.9% | 24.8% | |
Cardiovascular — Segment Net Sales at Constant Currency ($M)($M) | 3,406 | 3,622 | 3,502 | 3,465 | 3,346 | 3,365 | 3,157 | 2,977 | 2,740 | ||||
Cardiovascular — Total Segment Operating Expenses ($M)($M)5 | 2,390 | 2,425 | 2,377 | 2,416 | 2,201 | 2,286 | 2,089 | 2,065 | 1,878 | ||||
Cardiovascular — Total Segment Expenses as % of Segment Sales (%)(%) | 70.2% | 66.9% | 67.9% | 69.7% | 65.8% | 67.9% | 66.2% | 69.4% | 68.5% | ||||
Cardiovascular — Segment Cost of Products Sold (ASU 2023-07, $M)($M)1 | 1,027 | 1,065 | 1,067 | 1,039 | 931 | 1,048 | 926 | 911 | 838 | 851 | 811 | ||
Cardiovascular — Segment Cost of Products Sold (% of Segment Sales)(%) | 30.1% | 29.4% | 30.5% | 27.8% | 31.2% | 29.3% | 30.6% | 31.9% | 33.0% | ||||
Cardiovascular — Segment SG&A Expenses (ASU 2023-07, $M)($M)1 | 985 | 992 | 959 | 971 | 926 | 915 | 873 | 874 | 791 | 796 | 740 | ||
Cardiovascular — Segment SG&A Expenses (% of Segment Sales)(%) | 28.9% | 27.4% | 27.4% | 27.7% | 27.2% | 27.7% | 28.9% | 29.9% | 30.1% | ||||
Cardiovascular — Segment R&D Expenses (ASU 2023-07, $M)($M)1 | 371 | 359 | 343 | 372 | 338 | 316 | 283 | 276 | 244 | 231 | 228 | ||
Cardiovascular — Segment R&D Expenses (% of Segment Sales)(%) | 10.9% | 9.9% | 9.8% | 10.1% | 9.4% | 9.0% | 8.9% | 8.7% | 9.3% | ||||
Cardiovascular — Other Segment Expense Items / Royalties (ASU 2023-07, $M)($M)1 | 8 | 8 | 7 | 7 | 6 | 6 | 6 | 5 | 5 | 5 | 4 | ||
Cardiovascular — Other Segment Expense Items (% of Segment Sales)(%) | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | ||||
Cardiovascular — Segment Depreciation Expense ($M)($M) | 97 | 93 | 89 | 105 | 89 | 83 | 78 | 91 | 75 | 71 | 66 | ||
Cardiovascular — Segment Goodwill Balance ($M)($M) | 10,569 | 10,558 | 10,560 | 10,574 | 10,528 | 10,550 | 9,841 | 9,606 | 9,684 | 9,057 | 9,019 | 9,041 | |
MedSurg — Segment Operating Income ($M)($M)6 | 545 | 598 | 533 | 554 | 572 | 606 | 536 | 563 | 518 | 522 | 485 | 550 | |
MedSurg — Segment Operating Margin (%)(%) | 31.4% | 32.9% | 31.3% | 33.2% | 35.1% | 33.3% | 34.9% | 34.9% | 34.2% | ||||
MedSurg — Adjusted Segment Operating Margin (%)(%) | 31.4% | 32.9% | 31.3% | 31.9% | 33.2% | 35.1% | 33.3% | 34.4% | 34.9% | 34.6% | 33.8% | 35.4% | |
MedSurg — Segment Net Sales at Constant Currency ($M)($M) | 1,735 | 1,818 | 1,700 | 1,803 | 1,723 | 1,725 | 1,609 | 1,636 | 1,484 | ||||
MedSurg — Total Segment Operating Expenses ($M)($M)5 | 1,190 | 1,221 | 1,167 | 1,228 | 1,151 | 1,119 | 1,074 | 1,074 | 965 | ||||
MedSurg — Total Segment Expenses as % of Segment Sales (%)(%) | 68.6% | 67.1% | 68.7% | 68.1% | 66.8% | 64.9% | 66.7% | 65.6% | 65.0% | ||||
MedSurg — Segment Cost of Products Sold (ASU 2023-07, $M)($M)1 | 504 | 526 | 478 | 529 | 483 | 470 | 435 | 457 | 412 | 401 | 381 | ||
MedSurg — Segment Cost of Products Sold (% of Segment Sales)(%) | 29.1% | 28.9% | 28.1% | 28.0% | 27.3% | 27.0% | 27.8% | 26.8% | 26.9% | ||||
MedSurg — Segment SG&A Expenses (ASU 2023-07, $M)($M)1 | 556 | 567 | 557 | 550 | 534 | 521 | 512 | 483 | 440 | 454 | 439 | ||
MedSurg — Segment SG&A Expenses (% of Segment Sales)(%) | 32.1% | 31.2% | 32.8% | 31.0% | 30.2% | 31.8% | 29.7% | 30.4% | 31.0% | ||||
MedSurg — Segment R&D Expenses (ASU 2023-07, $M)($M)1 | 126 | 124 | 127 | 137 | 129 | 120 | 121 | 128 | 113 | 114 | 107 | ||
MedSurg — Segment R&D Expenses (% of Segment Sales)(%) | 7.2% | 6.8% | 7.5% | 7.5% | 7.0% | 7.5% | 7.6% | 7.6% | 7.6% | ||||
MedSurg — Other Segment Expense Items / Royalties (ASU 2023-07, $M)($M)1 | 4 | 4 | 5 | 2 | 5 | 8 | 6 | 5 | 0 | 4 | 5 | ||
MedSurg — Other Segment Expense Items (% of Segment Sales)(%) | 0.3% | 0.2% | 0.3% | 0.3% | 0.4% | 0.3% | 0.0% | 0.3% | 0.3% | ||||
MedSurg — Segment Depreciation Expense ($M)($M) | 31 | 29 | 29 | 31 | 29 | 28 | 27 | 31 | 27 | 27 | 24 | ||
MedSurg — Segment Goodwill Balance ($M)($M) | 8,167 | 8,082 | 7,977 | 7,709 | 7,686 | 7,526 | 7,500 | 7,483 | 5,349 | 5,341 | 5,342 | 5,347 | |
Total Reportable Segments — Operating Income ($M)($M)7 | 1,350 | 1,272 | 1,128 | ||||||||||
Total Reportable Segments — Adjusted Operating Income at Constant Currency ($M)($M) | 1,560 | 1,795 | 1,658 | 1,624 | 1,718 | 1,685 | 1,604 | 1,474 | 1,380 | ||||
Total Reportable Segments — Net Sales at Constant Currency ($M)($M) | 5,141 | 5,440 | 5,202 | 5,268 | 5,069 | 5,090 | 4,766 | 4,614 | 4,224 | ||||
Total Reportable Segments — Combined Segment Expenses ($M)($M) | 3,580 | 3,646 | 3,544 | 3,644 | 3,352 | 3,405 | 3,163 | 3,139 | 2,843 | ||||
Unallocated Corporate Expenses & FX Hedging Impact ($M)($M) | -196 | -252 | -199 | -179 | -299 | -286 | -255 | -224 | 203 | 153 | 115 | -581 | |
Unallocated Acquisition, Restructuring, Litigation, Impairment & EU MDR Charges ($M)($M) | -302 | -132 | -126 | -392 | -146 | -355 | -209 | -351 | 209 | 386 | 124 | ||
Unallocated Intangible Amortization Expense ($M)($M) | -234 | -233 | -232 | -228 | -225 | -225 | -219 | -225 | -205 | ||||
Total Reportable Segments — Combined Segment Assets ($M)($M) | 12,456 | 12,259 | 11,977 | 11,391 | 11,191 | 10,829 | 10,540 | 10,177 | 8,876 | ||||
United States — Regional Net Sales ($M)($M)3 | 3,309 | 3,426 | 3,284 | 3,385 | 3,294 | 3,224 | 2,960 | 2,893 | 2,593 | 2,466 | 2,258 | 2,213 | |
United States — Operational Sales Growth (%)(%) | 0.5% | 6.2% | 10.9% | 17.0% | 27.0% | 30.7% | 31.1% | 30.7% | 23.5% | 16.9% | 12.7% | 11.4% | |
United States — Reported Sales Growth (%)(%) | 0.5% | 6.2% | 10.9% | 17.0% | 27.0% | 30.7% | 31.1% | 30.7% | 23.5% | 16.9% | 12.7% | 11.4% | |
United States — Foreign Currency Impact (%)(%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
International Total (Non-U.S.) — Regional Net Sales ($M)($M)4 | 1,829 | 2,017 | 1,920 | 1,901 | 1,770 | 1,837 | 1,702 | 1,669 | 1,616 | 1,654 | 1,599 | 1,513 | |
Europe, Middle East & Africa (EMEA) — Net Sales ($M)($M)3 | 829 | 932 | 932 | 933 | 793 | 878 | 846 | 830 | 773 | 822 | 803 | 749 | |
EMEA — Operational Sales Growth (%)(%) | 6.1% | 4.2% | 1.2% | 4.8% | -2.0% | 1.8% | 7.9% | 11.6% | 14.3% | 16.1% | 13.3% | 11.6% | |
EMEA — Reported Sales Growth (%)(%) | 4.4% | 6.1% | 10.1% | 12.4% | 2.6% | 6.8% | 5.5% | 10.8% | 15.2% | 13.7% | 12.7% | 14.0% | |
EMEA — Foreign Currency Impact (%)(%) | 1.7% | -1.9% | -8.8% | -7.6% | -4.6% | -5.0% | 2.4% | 0.9% | -1.0% | 2.5% | 0.6% | -2.4% | |
Asia-Pacific (APAC) — Net Sales ($M)($M)3 | 797 | 878 | 803 | 788 | 802 | 790 | 701 | 684 | 684 | 670 | 647 | 616 | |
APAC — Operational Sales Growth (%)(%) | -1.1% | 11.2% | 12.0% | 14.8% | 16.9% | 15.4% | 10.6% | 12.4% | 12.3% | 13.2% | 25.9% | 17.0% | |
APAC — Reported Sales Growth (%)(%) | -0.6% | 11.2% | 14.7% | 15.2% | 17.1% | 18.0% | 8.2% | 11.1% | 12.1% | 7.0% | 18.3% | 14.8% | |
APAC — Foreign Currency Impact (%)(%) | -0.4% | -0.0% | -2.7% | -0.4% | -0.2% | -2.6% | 2.4% | 1.2% | 0.2% | 6.2% | 7.6% | 2.2% | |
Latin America & Canada (LACA) — Net Sales ($M)($M)3 | 203 | 206 | 185 | 179 | 175 | 169 | 155 | 155 | 159 | 162 | 149 | 148 | |
LACA — Operational Sales Growth (%)(%) | 10.5% | 16.2% | 12.0% | 10.4% | 9.6% | 8.9% | 14.1% | 12.6% | 15.1% | 15.7% | 12.7% | 14.6% | |
LACA — Reported Sales Growth (%)(%) | 16.0% | 22.4% | 19.0% | 15.9% | 10.4% | 4.0% | 4.4% | 4.6% | 9.0% | 15.3% | 17.9% | 20.8% | |
LACA — Foreign Currency Impact (%)(%) | -5.5% | -6.2% | -7.0% | -5.5% | -0.8% | 4.9% | 9.6% | 8.0% | 6.1% | 0.4% | -5.1% | -6.2% | |
Emerging Markets — Net Sales ($M)($M)3 | 771 | 765 | 758 | 690 | 668 | 684 | 680 | 648 | 595 | ||||
Emerging Markets — Operational Sales Growth (%)(%) | 13.0% | 11.5% | 12.1% | 9.8% | 15.2% | 16.8% | 19.3% | 28.2% | 18.7% | ||||
Emerging Markets — Reported Sales Growth (%)(%) | 15.4% | 11.8% | 11.6% | 6.5% | 12.4% | 15.2% | 14.8% | 22.6% | 16.3% | ||||
Emerging Markets — Foreign Currency Impact (%)(%) | -2.5% | -0.2% | 0.5% | 3.3% | 2.8% | 1.5% | 4.6% | 5.5% | 2.4% | ||||
Long-Lived Tangible Assets — United States ($M)($M)3 | 1,998 | 1,984 | 1,948 | 1,919 | 1,812 | 1,530 | 1,522 | 1,461 | 1,300 | ||||
Long-Lived Tangible Assets — Ireland ($M)($M) | 755 | 752 | 750 | 750 | 707 | 701 | 655 | 631 | 598 | ||||
Long-Lived Tangible Assets — Costa Rica ($M)($M) | 656 | 647 | 640 | 637 | 593 | 574 | 557 | 530 | 373 | ||||
Long-Lived Tangible Assets — Rest of World ($M)($M) | 774 | 743 | 725 | 730 | 683 | 656 | 654 | 672 | 587 | ||||
Adjusted Gross Profit (Non-GAAP, $M)($M)5 | 3,493 | 3,824 | 3,668 | 3,735 | 3,595 | 3,514 | 3,332 | 3,222 | 2,962 | 2,899 | 2,692 | 2,621 | |
Adjusted Gross Margin (Non-GAAP, %)(%) | 68.0% | 70.3% | 70.5% | 70.7% | 71.0% | 69.4% | 71.5% | 70.6% | 70.4% | 70.4% | 69.8% | 70.4% | |
GAAP Gross Margin, as Reported (%)(%) | 66.7% | 70.7% | 69.4% | 69.6% | 69.9% | 67.7% | 68.8% | 67.9% | 68.8% | 69.2% | 68.7% | 69.2% | |
Gross Margin YoY Bridge — Pricing, Volume & Product Mix Impact (bps / %)(%) | -0.3% | 0.6% | 0.8% | 1.8% | 1.6% | 2.1% | 0.9% | -0.3% | 0.5% | ||||
Gross Margin YoY Bridge — Foreign Currency Fluctuations Impact (bps / %)(%) | -0.2% | -0.4% | -0.8% | 0.2% | -0.3% | ||||||||
Gross Margin YoY Bridge — Manufacturing & Other Period Expense Impact (bps / %)(%) | -1.1% | 2.9% | 0.7% | -0.7% | -3.1% | -1.9% | -0.9% | -1.3% | -0.9% | ||||
Adjusted Operating Income (Non-GAAP, $M)($M)6 | 1,364 | 1,543 | 1,459 | 1,444 | 1,419 | 1,399 | 1,350 | 1,251 | 1,147 | 1,119 | 1,012 | 990 | |
Adjusted Operating Margin (Non-GAAP, %)(%) | 26.5% | 28.4% | 28.0% | 27.3% | 28.0% | 27.6% | 28.9% | 27.4% | 27.2% | 27.2% | 26.2% | 26.6% | |
GAAP Operating Margin, as Reported (%)(%) | 16.1% | 21.6% | 21.2% | 15.6% | 20.7% | 16.2% | 19.8% | 14.8% | 17.4% | 12.6% | 17.5% | 15.7% | |
Adjusted Total Operating Expenses (Non-GAAP, $M)($M) | 2,128 | 2,281 | 2,209 | 2,291 | 2,175 | 2,114 | 1,982 | 1,971 | 1,815 | 1,780 | 1,680 | 1,631 | |
Adjusted SG&A Expenses (Non-GAAP, $M)2 | |||||||||||||
Adjusted SG&A as % of Net Sales (Non-GAAP, %)(%) | 31.8% | 32.3% | 32.8% | 33.1% | 33.1% | 32.2% | 33.2% | 33.6% | 33.9% | 34.1% | 34.3% | 34.2% | |
GAAP SG&A as % of Net Sales (%)(%) | 32.7% | 33.1% | 34.2% | 34.7% | 34.4% | 33.9% | 34.2% | 35.3% | 37.1% | 35.1% | 35.4% | 37.0% | |
Adjusted R&D Expenses (Non-GAAP, $M)2 | |||||||||||||
Adjusted R&D as % of Net Sales (Non-GAAP, %)(%) | 9.4% | 9.4% | 9.4% | 10.1% | 9.6% | 9.3% | 9.1% | 9.4% | 9.1% | 8.9% | 9.1% | 9.2% | |
GAAP R&D as % of Net Sales (%)(%) | 10.1% | 10.2% | 9.9% | 10.8% | 10.1% | 10.4% | 9.5% | 10.1% | 9.7% | 9.3% | 9.5% | 9.7% | |
Royalty Expense as % of Net Sales (%)(%) | 0.2% | 0.2% | 0.2% | 0.1% | 0.2% | 0.3% | 0.3% | 0.2% | 0.1% | 0.2% | 0.2% | 0.3% | |
Adjusted Net Income Attributable to Common Stockholders (Non-GAAP, $M)($M)11 | 1,063 | 1,275 | 1,189 | 1,201 | 1,124 | 1,127 | 1,121 | 1,043 | 937 | 914 | 832 | 817 | |
Adjusted Diluted Earnings Per Share (Non-GAAP, $/sh) | 0.73 | 0.86 | 0.80 | 0.80 | 0.75 | 0.75 | 0.75 | 0.70 | 0.63 | 0.62 | 0.56 | 0.55 | |
Adjusted Pre-Tax Income (Non-GAAP, $M)($M) | 1,240 | 1,423 | 1,347 | 1,345 | 1,303 | 1,289 | 1,243 | 1,164 | 1,082 | 1,051 | 932 | 911 | |
Adjusted Effective Tax Rate (Non-GAAP, %)(%) | 14.3% | 10.4% | 11.7% | 10.7% | 12.5% | 12.5% | 9.8% | 10.5% | 13.2% | 12.5% | 13.0% | 10.0% | |
Operational Effective Tax Rate (Non-GAAP, %)(%) | 17.6% | 17.3% | 17.4% | 14.9% | 13.9% | 14.2% | 13.6% | 12.3% | 13.5% | 13.5% | 14.0% | 14.6% | |
GAAP Effective Tax Rate, as Reported (%)(%) | 20.8% | 14.6% | -15.2% | 4.3% | 19.5% | 15.5% | 16.5% | 3.9% | 30.0% | 19.0% | 19.0% | 0.3% | |
Non-GAAP Adjustment — Intangible Asset Amortization ($M)($M) | 234 | 233 | 232 | 228 | 225 | 225 | 219 | 225 | 205 | 213 | 214 | 208 | |
Non-GAAP Adjustment — Acquisition & Divestiture-Related Net Charges ($M)($M) | 82 | 91 | 83 | 89 | 99 | 138 | 148 | 147 | 143 | 48 | 64 | 129 | |
Non-GAAP Adjustment — Restructuring & Restructuring-Related Net Charges ($M)($M) | 94 | 42 | 35 | 97 | 36 | 161 | 49 | 80 | 52 | 50 | 46 | 52 | |
Non-GAAP Adjustment — Litigation-Related Net Charges ($M)($M) | 81 | 76 | 194 | ||||||||||
Non-GAAP Adjustment — Goodwill & Intangible Asset Impairment Charges ($M)($M) | 39 | 0 | 46 | 111 | 276 | ||||||||
Non-GAAP Adjustment — EU Medical Device Regulation (MDR) Implementation Costs ($M)($M) | 5 | 7 | 7 | 12 | 11 | 10 | 12 | 13 | 13 | 12 | 14 | 16 | |
Days Sales Outstanding (DSO, days)(ngày) | 56 | 51 | 52 | 51 | 51 | 51 | 52 | 52 | 55 | 53 | 54 | 55 | |
Days Inventory on Hand (DIOH, days)(ngày)4 | 178 | 185 | 177 | 168 | 177 | 159 | 178 | 176 | 193 | 187 | 193 | 199 | |
Inventories — Finished Goods ($M)($M) | 1,971 | 1,972 | 1,931 | 1,849 | 1,827 | 1,808 | 1,805 | 1,798 | 1,687 | 1,558 | 1,555 | 1,537 | |
Inventories — Work-in-Process ($M)($M) | 311 | 277 | 259 | 246 | 245 | 218 | 218 | 193 | 206 | 201 | 188 | 174 | |
Inventories — Raw Materials ($M)($M) | 1,035 | 985 | 928 | 849 | 849 | 835 | 843 | 819 | 860 | 849 | 818 | 773 | |
Acquisition Inventory Fair Value Step-Up Amortization ($M)($M) | 2 | 4 | 2 | 5 | 9 | 37 | 81 | 51 | 0 | 0 | 0 | 0 | |
Adjusted EBITDA (Non-GAAP, $M)($M)7 | 1,464 | 1,630 | 1,540 | 1,558 | 1,502 | 1,487 | 1,426 | 1,344 | 1,221 | 1,196 | 1,078 | 1,070 | |
Trailing 12-Month (TTM) Adjusted EBITDA ($M)($M) | 6,192 | 6,230 | 6,087 | 5,973 | 5,759 | 5,478 | 5,187 | 4,839 | 4,565 | 4,335 | 4,167 | 4,017 | |
GAAP EBITDA ($M)($M) | 1,191 | 1,500 | 1,588 | 1,141 | 1,362 | 1,364 | 1,207 | 990 | 1,013 | 778 | 967 | 873 | |
Trailing 12-Month (TTM) GAAP EBITDA ($M)($M) | 5,419 | 5,590 | 5,455 | 5,073 | 4,923 | 4,574 | 3,987 | 3,748 | 3,631 | 3,589 | 3,604 | 3,424 | |
Gross Total Debt (EBITDA Reconciliation Basis, $M)($M) | 11,952 | 12,624 | 11,029 | 11,436 | 11,600 | 11,587 | 11,309 | 10,746 | 10,885 | 10,571 | 10,619 | 9,102 | |
Gross Debt to Adjusted EBITDA Leverage Ratio (x) | 1.90 | 2.00 | 1.80 | 1.90 | 2.00 | 2.10 | 2.20 | 2.20 | 2.40 | 2.40 | 2.50 | 2.30 | |
Revolving Credit Facility Consolidated Leverage Ratio — Actual (x) | 1.95 | 2.02 | 1.87 | 1.92 | 2.02 | 2.16 | 2.21 | 2.26 | 1.95 | 1.97 | 2.08 | 2.33 | |
Revolving Credit Facility Consolidated Leverage Ratio — Maximum Covenant Limit (x) | 3.75 | 4.00 | 4.25 | 4.75 | 4.75 | 4.75 | 3.75 | 3.75 | 3.75 | ||||
Contract Liabilities / Deferred Revenue Balance ($M)($M)1 | 711 | 691 | 686 | 682 | 668 | 662 | 641 | 635 | 618 | 599 | 593 | 577 | |
Revenue Recognized from Beginning Contract Liability Balance ($M)($M) | 74 | 63 | 65 | 68 | 68 | 54 | 57 | 59 | 62 | 49 | |||
Acquisition Contingent Consideration Liability Carrying Value ($M)($M)1 | 246 | 257 | 354 | 385 | 378 | 367 | 214 | 171 | 171 | 293 | 273 | 404 | |
Contingent Consideration Fair Value Remeasurement Net Expense (Benefit) ($M)($M) | -32 | -16 | -30 | 7 | 11 | -5 | 5 | -1 | -23 | 2 | 17 | 15 | |
Legal & Product Liability Accrual Reserve Carrying Balance ($M)($M)1 | 370 | 282 | 229 | 242 | 306 | 300 | 316 | 326 | 250 | 251 | 283 | 377 | |
Litigation & Product Liability Settlement Net Charges ($M)($M) | 81 | 76 | 0 | 194 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Restructuring Accrual Reserve Balance ($M)($M)1 | 48 | 59 | 26 | 41 | |||||||||
Restructuring Charges Incurred ($M)($M) | 63 | 8 | 3 | 16 | -8 | 83 | 10 | 4 | 8 | 1 | 3 | 18 | |
Other Intangible Assets — Gross Carrying Value ($M)($M)8 | 18,322 | 18,094 | 17,992 | 17,667 | 17,577 | 17,446 | 17,293 | 17,188 | 16,181 | 15,510 | 15,863 | 15,817 | |
Intangible Assets — Technology-Related Gross ($M)($M) | 15,259 | 15,065 | 14,985 | 14,692 | 14,634 | 14,530 | 14,406 | 14,327 | 13,431 | 12,846 | 13,223 | 13,207 | |
Intangible Assets — Patents Gross ($M)($M) | 510 | 502 | 497 | 493 | 492 | 483 | 481 | 481 | 480 | 476 | 480 | 480 | |
Indefinite-Lived In-Process R&D (IPR&D) Intangible Assets ($M)($M) | 730 | 770 | 770 | 813 | 813 | 813 | 94 | 94 | 94 | 94 | 54 | 54 | |
Estimated Future Intangible Amortization — Year 1 ($M)($M) | 881 | 893 | 828 | ||||||||||
Estimated Future Intangible Amortization — Year 2 ($M)($M) | 869 | 874 | 757 | ||||||||||
Estimated Future Intangible Amortization — Year 3 ($M)($M) | 831 | 835 | 737 | ||||||||||
Estimated Future Intangible Amortization — Year 4 ($M)($M) | 786 | 787 | 714 | ||||||||||
Estimated Future Intangible Amortization — Year 5 ($M)($M) | 625 | 769 | 690 | ||||||||||
Operating Lease Liabilities — Total ($M)($M)3 | 536 | 482 | 466 | ||||||||||
Operating Lease Right-of-Use (ROU) Assets ($M)($M) | 537 | 553 | 547 | 465 | 495 | 492 | 448 | 449 | 426 | 416 | 430 | 439 | |
Operating Leases Weighted-Average Discount Rate (%)(%) | 4.1% | 3.9% | 4.5% | ||||||||||
Undiscounted Future Operating Lease Payments — Total ($M)($M) | 656 | 564 | 539 | ||||||||||
Unrecognized Tax Benefits (UTB) Balance ($M)($M)1 | 637 | 636 | 609 | 596 | 529 | 531 | 514 | 506 | 493 | 478 | 465 | 467 | |
Unrecognized Tax Benefits That Would Impact Effective Tax Rate if Recognized ($M)($M) | 536 | 536 | 512 | 501 | 444 | 447 | 431 | 423 | 417 | 406 | 393 | 395 | |
Axonics, Inc. (Acquired Nov 2024 — Urology) — Total Net Revenue ($M)($M)9 | 116 | 115 | 91.4 | 110 | |||||||||
Axonics — Sacral Neuromodulation (SNM) Worldwide Revenue ($M)($M)2 | 92.4 | 91.2 | 71.7 | 88.5 | |||||||||
Axonics — Sacral Neuromodulation U.S. Revenue ($M)($M) | 90.1 | 89.1 | 69.8 | 86.6 | |||||||||
Axonics — Sacral Neuromodulation International Revenue ($M)($M) | 2.28 | 2.14 | 1.84 | 1.93 | |||||||||
Axonics — Bulkamid Urethral Bulking Hydrogel Worldwide Revenue ($M)($M)2 | 23.8 | 23.4 | 19.7 | 21.2 | |||||||||
Axonics — Bulkamid U.S. Revenue ($M)($M) | 19.1 | 18.3 | 15.2 | 17.0 | |||||||||
Axonics — Bulkamid International Revenue ($M)($M) | 4.79 | 5.04 | 4.51 | 4.19 | |||||||||
Axonics — Gross Profit ($M)($M) | 89.7 | 89.1 | 69.3 | 82.8 | |||||||||
Axonics — Cost of Goods Sold ($M)($M) | 26.5 | 25.4 | 22.2 | 27.0 | |||||||||
Axonics — Research & Development Expense ($M)($M) | 13.5 | 12.8 | 11.1 | 9.72 | |||||||||
Axonics — Operating Income (Loss) ($M)($M) | -6.27 | 3.68 | -19.2 | 1.06 | |||||||||
Axonics — Net Income (Loss) ($M)($M) | -0.02 | 6.90 | -19.1 | 6.61 | |||||||||
Axonics — Operating Cash Flow ($M)($M) | 0.92 | 17.0 | -9.24 | 5.63 | |||||||||
Axonics — Total Inventories ($M)($M) | 114 | 105 | 93.2 | 79.9 | |||||||||
Silk Road Medical, Inc. (Acquired Sep 2024 — TCAR Vascular) — Total Net Revenue ($M)($M)8 | 51.2 | 48.5 | 47.3 | ||||||||||
Silk Road Medical — Gross Profit ($M)($M) | 38.5 | 36.5 | 34.8 | ||||||||||
Silk Road Medical — Cost of Goods Sold ($M)($M) | 12.7 | 12.0 | 12.5 | ||||||||||
Silk Road Medical — Research & Development Expense ($M)($M) | 11.9 | 10.7 | 10.1 | ||||||||||
Silk Road Medical — SG&A Expense ($M)($M) | 43.8 | 40.8 | 39.1 | ||||||||||
Silk Road Medical — Operating Loss ($M)($M) | -17.2 | -14.9 | -14.4 | ||||||||||
Silk Road Medical — Net Loss ($M)($M) | -16.6 | -14.1 | -13.0 | ||||||||||
Silk Road Medical — Operating Cash Flow ($M)($M) | -3.38 | -15.3 | -8.45 | ||||||||||
Silk Road Medical — Total Inventories ($M)($M) | 29.7 | 30.5 | 29.9 | ||||||||||
U.S. FDA 510(k) Premarket Notification Clearances — Boston Scientific (clearances)1 | 10.00 | 4.00 | 4.00 | 4.00 | 6.00 | 4.00 | 3.00 | 5.00 | 6.00 | 2.00 | 3.00 | 7.00 | |
U.S. FDA 510(k) Clearances — Total U.S. Medical Device Industry (clearances) | 855.00 | 923.00 | 756.00 | 806.00 | 797.00 | 886.00 | 736.00 | 856.00 | 767.00 | 793.00 | 713.00 | 877.00 | |
U.S. FDA Premarket Approval (PMA) Original & Supplement Approvals — Boston Scientific (approvals)1 | 48.00 | 67.00 | 58.00 | 40.00 | 43.00 | 28.00 | 39.00 | 57.00 | 46.00 | 54.00 | 49.00 | 68.00 | |
U.S. FDA PMA Approvals — Total U.S. Medical Device Industry (approvals) | 565.00 | 608.00 | 567.00 | 525.00 | 585.00 | 588.00 | 524.00 | 683.00 | 538.00 | 550.00 | 459.00 | 656.00 | |
U.S. FDA MAUDE Adverse Event MDR Reports — Boston Scientific Total (reports)6 | 20,320.00 | 20,617.00 | 20,500.00 | 20,508.00 | 19,673.00 | 17,610.00 | 16,030.00 | 16,967.00 | 15,626.00 | 15,919.00 | 16,221.00 | 15,503.00 | |
FDA MAUDE MDR Reports — Boston Scientific Patient Injury Events (reports) | 9,593.00 | 10,030.00 | 11,305.00 | 11,502.00 | 10,184.00 | 10,166.00 | 9,489.00 | 10,200.00 | 9,246.00 | 9,289.00 | 9,865.00 | 9,514.00 | |
FDA MAUDE MDR Reports — Boston Scientific Device Malfunction Events (reports) | 10,376.00 | 10,320.00 | 8,925.00 | 8,832.00 | 9,234.00 | 7,233.00 | 6,262.00 | 6,642.00 | 6,252.00 | 6,448.00 | 6,087.00 | 5,853.00 | |
FDA MAUDE MDR Reports — Boston Scientific Death Events (reports) | 304.00 | 262.00 | 270.00 | 169.00 | 253.00 | 210.00 | 276.00 | 123.00 | 127.00 | 179.00 | 269.00 | 130.00 | |
FDA MAUDE MDR Reports — Total U.S. Medical Device Industry (reports) | 1,189,467.00 | 923,529.00 | 811,618.00 | 751,012.00 | 819,444.00 | 632,296.00 | 685,251.00 | 709,498.00 | 699,798.00 | 631,546.00 | 586,309.00 | 573,619.00 | |
U.S. FDA Device Recall Events — Boston Scientific (recalls) | 36.00 | 9.00 | 8.00 | 34.00 | 30.00 | 4.00 | 20.00 | 32.00 | 40.00 | 54.00 | 6.00 | 18.00 | |
U.S. FDA Device Enforcement Recall Actions — Boston Scientific (actions) | 37.00 | 8.00 | 8.00 | 35.00 | 29.00 | 4.00 | 20.00 | 63.00 | 9.00 | 58.00 | 2.00 | 18.00 | |
NIH ClinicalTrials.gov — Boston Scientific Studies Started in Period (studies) | 11.00 | 11.00 | 9.00 | 10.00 | 8.00 | 12.00 | 10.00 | 8.00 | 5.00 | 12.00 | 8.00 | 9.00 | |
U.S. Producer Price Index — Surgical & Medical Instrument Manufacturing (NAICS 339112, index)1 | |||||||||||||
U.S. Census Quarterly Services Survey — Total U.S. Hospital Revenue (NAICS 622, $M)($M) | 47,896 | 46,674 | 46,834 | 46,295 | 45,370 | 45,358 | 45,284 | 43,778 | 43,505 | 43,709 | 43,264 | ||
Net Sales (GAAP, $M)($M)7 | 5,138 | 5,442 | 5,203 | 5,286 | 5,065 | 5,061 | 4,663 | 4,561 | 4,209 | 4,120 | 3,856 | 3,725 | |
Gross Profit (GAAP, $M)($M) | 3,428 | 3,848 | 3,614 | 3,679 | 3,542 | 3,424 | 3,210 | 3,095 | 2,897 | 2,850 | 2,648 | 2,579 | |
Cost of Products Sold (GAAP, $M)($M) | 1,710 | 1,594 | 1,590 | 1,608 | 1,523 | 1,637 | 1,453 | 1,466 | 1,312 | 1,270 | 1,209 | 1,147 | |
Selling, General & Administrative Expenses (GAAP, $M)($M) | 1,683 | 1,803 | 1,781 | 1,834 | 1,741 | 1,716 | 1,597 | 1,612 | 1,562 | 1,446 | 1,364 | 1,379 | |
Research & Development Expenses (GAAP, $M)($M) | 520 | 554 | 516 | 569 | 514 | 526 | 443 | 459 | 407 | 383 | 366 | 363 | |
Operating Income (Loss) (GAAP, $M)($M) | 828 | 1,178 | 1,101 | 825 | 1,048 | 819 | 921 | 675 | 733 | 520 | 675 | 584 | |
Net Income (Loss) Attributable to Common Stockholders (GAAP, $M)($M) | 582 | 907 | 1,341 | 672 | 755 | 797 | 674 | 565 | 469 | 324 | 495 | 505 | |
Diluted Earnings Per Share (GAAP, $/sh) | 0.40 | 0.61 | 0.90 | 0.51 | 0.53 | 0.45 | 0.32 | 0.22 | 0.33 | ||||
Operating Cash Flow (GAAP, $M)($M)2 | 1,048 | 1,474 | 348 | 1,364 | 1,343 | 1,286 | 541 | 1,456 | 1,002 | 813 | 164 | 957 | |
Capital Expenditures (GAAP, $M)($M) | 180 | 195 | 177 | 351 | 181 | 157 | 187 | 277 | 179 | 155 | 179 | 267 | |
Stock-Based Compensation Expense ($M)($M) | 72 | 87 | 83 | 71 | 79 | 75 | 74 | 69 | 68 | 66 | 63 | 59 | |
Total Assets (GAAP, $M)($M)6 | 45,461 | 45,216 | 44,351 | 43,673 | 42,707 | 41,559 | 40,140 | 39,395 | 38,078 | 37,108 | 36,669 | 35,136 | |
Cash and Cash Equivalents ($M)($M) | 609 | 539 | 1,453 | 1,965 | 1,275 | 534 | 725 | 606 | 2,502 | 2,913 | 2,329 | 865 | |
Total Inventories ($M)($M) | 3,317 | 3,235 | 3,117 | 2,943 | 2,921 | 2,861 | 2,867 | 2,810 | 2,753 | 2,608 | 2,561 | 2,484 | |
Property, Plant & Equipment, Net ($M)($M) | 4,183 | 4,126 | 4,063 | 4,036 | 3,795 | 3,461 | 3,389 | 3,294 | 3,072 | 2,951 | 2,897 | 2,859 | |
Goodwill ($M)($M) | 18,736 | 18,640 | 18,536 | 18,282 | 18,214 | 18,076 | 17,340 | 17,089 | 15,033 | 14,397 | 14,361 | 14,387 | |
Other Intangible Assets, Net ($M)($M) | 6,860 | 6,918 | 7,060 | 7,019 | 7,162 | 7,260 | 6,566 | 6,684 | 5,754 | 5,417 | 5,839 | 6,003 | |
Total Stockholders' Equity ($M)($M) | 25,630 | 24,930 | 25,864 | 24,233 | 23,394 | 22,418 | 22,212 | 21,770 | 20,708 | 20,371 | 19,926 | 19,282 | |
50 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Business Unit × Geography Revenue & Organic Growth Bridge (Groups 1–2): Full disaggregation across Cardiovascular (Interventional Cardiology & Vascular Therapies [ICVT] with standalone Interventional Cardiology and Vascular Therapies sub-units, Watchman, Electrophysiology, Cardiac Rhythm Management, Interventional Oncology & Embolization, plus legacy ICTx, Cardiology, and Peripheral Interventions) and MedSurg (Endoscopy, Urology, Neuromodulation), split by United States, International, and Worldwide with Reported, Foreign Currency, Operational (Constant Currency), M&A, and Organic growth bridges.
- Segment Operating Profitability & ASU 2023-07 Significant Segment Expenses (Group 3): Resolves the post-FY2019 Segment Operating Income gap in standard segment tables by extracting GAAP Segment Operating Income ($M & %), Constant-Currency Adjusted Segment Operating Income ($M & %), and ASU 2023-07 Segment Cost of Products Sold, Segment SG&A, Segment R&D, and Other Segment Expenses ($M & % of segment sales) for Cardiovascular and MedSurg.
- Working Capital, Leverage, Clinical/ESG, Subsidiaries & Regulatory Benchmarks (Groups 5–8): Rolling quarterly DSO (56 days in Q3 2026) and DIOH (178 days in Q3 2026), quarterly GAAP/Adjusted EBITDA and Gross Debt / Adjusted EBITDA (1.9x in Q3 2026), 8-year clinical/quality/workforce/EHS/environmental series (FY2018–FY2025), pre-acquisition standalone filings for Axonics (NASDAQ: AXNX) and Silk Road Medical (NASDAQ: SILK), UK statutory gender pay gap filings for Boston Scientific Limited, and monthly/quarterly openFDA (510(k), PMA, Recalls, MAUDE MDR), ClinicalTrials.gov, and FRED series.
- Consolidated vs. Standalone Assessment: Boston Scientific Corporation reports consolidated financial statements under U.S. GAAP without separate parent-only income statements; subsidiary performance is presented directly from self-reported SEC and UK statutory filings in Group 7.
Không hiện vì thiếu các kỳ gần đây (14)
- Annual Patients Treated Worldwide ('more than 48 million patients in 2025', 'over 44 million in 2024', 'over 37 million in 2023') — Always disclosed as lower bounds ('more than', 'over', '33+ million') in Annual Reports and Impact Reports; excluded from main table per bound-number rule.
- Cumulative WATCHMAN Patients Treated ('more than 500,000 / 600,000 patients worldwide') — Disclosed only as cumulative milestone bounds ('more than', 'over') on earnings calls and presentations; excluded per bound-number rule.
- Cumulative FARAPULSE PFA Patients Treated ('more than 200,000 / 500,000 patients') — Disclosed as cumulative milestone bounds in earnings call commentary; excluded per bound-number rule.
- Customer-Facing Sales & Marketing Compliance Training Hours ('10,000+ in 2023, 14,000+ in 2024, 16,000+ in 2025') — Reported with '+' lower-bound suffix in 2025 Impact Report Data Pack; excluded per bound-number rule.
- Active Direct and Indirect Suppliers ('11,000+ suppliers') — Reported with '+' lower-bound suffix in 2025 Impact Report Data Pack; exact Tier 1 (1,148) and Critical Tier 1 (92) counts are included.
- Global Gender & Multicultural Pay Equity ('99%+' in 2023 and 2025; 'Analysis not completed' in 2024) — Reported as '99%+' bound and only biennially; excluded per bound-number and continuity rules.
- Remaining Performance Obligations (RPO) in Form 10-K Note A — Not disclosed as a quantitative dollar series because Boston Scientific elects the ASC 606 practical expedient for contracts with original durations of one year or less.
- Product Warranty Accrual Rollforward — Disclosed in Form 10-K Note A as immaterial to consolidated financial statements without a quantitative table.
- Segment Operating Profitability & Significant Segment Expenses (ASU 2023-07 & Non-GAAP) › Total Reportable Segments — Operating Income ($M) › Rhythm & Neuro (Legacy Pre-2021 Segment) — Operating Income ($M) › Rhythm & Neuro (Legacy Pre-2021 Segment) — Operating Margin (%)
- Non-GAAP Earnings Bridge, Working Capital Efficiency (DSO / DIOH) & Credit Leverage › Adjusted Gross Profit (Non-GAAP, $M) › Adjusted Cost of Products Sold (Non-GAAP, $M)
- Non-GAAP Earnings Bridge, Working Capital Efficiency (DSO / DIOH) & Credit Leverage › Adjusted Operating Income (Non-GAAP, $M) › Adjusted SG&A Expenses (Non-GAAP, $M)
- Non-GAAP Earnings Bridge, Working Capital Efficiency (DSO / DIOH) & Credit Leverage › Adjusted Operating Income (Non-GAAP, $M) › Adjusted R&D Expenses (Non-GAAP, $M)
- Non-GAAP Earnings Bridge, Working Capital Efficiency (DSO / DIOH) & Credit Leverage › Free Cash Flow Conversion (% of Adjusted Net Income) › Operating Cash Flow Conversion (% of GAAP Net Income)
- Non-GAAP Earnings Bridge, Working Capital Efficiency (DSO / DIOH) & Credit Leverage › Remaining Share Repurchase Authorization ($M)
Dữ liệu cập nhật 2026-11-04.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Cardiovascular Segment — Business Unit × Geography Revenue & Organic Growth Bridge
- Cardiovascular Segment — Worldwide Net Sales ($M) ($M)35 kỳ
- Interventional Cardiology & Vascular Therapies (ICVT) — Worldwide Net Sales ($M) ($M)11 kỳ
- Watchman (Left Atrial Appendage Closure — LAAC) — Worldwide Net Sales ($M) ($M)23 kỳ
- Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) — Worldwide Net Sales ($M) ($M)35 kỳ
- Cardiac Rhythm Management (CRM) — Worldwide Net Sales ($M) ($M)35 kỳ
- Interventional Oncology & Embolization (IO&E) — Worldwide Net Sales ($M) ($M)11 kỳ
- Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) — Worldwide Net Sales ($M) ($M)19 kỳ
- Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) — Worldwide Net Sales ($M) ($M)19 kỳ
- Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) — Worldwide Net Sales ($M) ($M)31 kỳ
- Interventional Cardiology (Legacy Pre-2022 Including Watchman) — Worldwide Net Sales ($M) ($M)16 kỳ
MedSurg Segment & Consolidated Company — Business Unit × Geography Revenue & Organic Growth Bridge
- MedSurg Segment — Worldwide Net Sales ($M) ($M)35 kỳ
- Endoscopy — Worldwide Net Sales ($M) ($M)35 kỳ
- Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) — Worldwide Net Sales ($M) ($M)35 kỳ
- Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) — Worldwide Net Sales ($M) ($M)35 kỳ
- Consolidated Total Company — Worldwide Net Sales ($M) ($M)35 kỳ
Segment Operating Profitability & Significant Segment Expenses (ASU 2023-07 & Non-GAAP)
Regional Commercial Revenue, Emerging Markets & Global Property Footprint
Non-GAAP Earnings Bridge, Working Capital Efficiency (DSO / DIOH) & Credit Leverage
- Adjusted Gross Profit (Non-GAAP, $M) ($M)26 kỳ
- Adjusted Operating Income (Non-GAAP, $M) ($M)35 kỳ
- Adjusted Net Income Attributable to Common Stockholders (Non-GAAP, $M) ($M)44 kỳ
- Days Sales Outstanding (DSO, days) (ngày)19 kỳ
- Days Inventory on Hand (DIOH, days) (ngày)19 kỳ
- Free Cash Flow Conversion (% of Adjusted Net Income) (%)2 kỳ
- Adjusted EBITDA (Non-GAAP, $M) ($M)18 kỳ
- Contract Liabilities / Deferred Revenue Balance ($M) ($M)34 kỳ
- Acquisition Contingent Consideration Liability Carrying Value ($M) ($M)35 kỳ
- Legal & Product Liability Accrual Reserve Carrying Balance ($M) ($M)51 kỳ
- Restructuring Accrual Reserve Balance ($M) ($M)5 kỳ
- Other Intangible Assets — Gross Carrying Value ($M) ($M)51 kỳ
- Operating Lease Liabilities — Total ($M) ($M)9 kỳ
- Unrecognized Tax Benefits (UTB) Balance ($M) ($M)50 kỳ
- Shipping & Handling Costs Included in SG&A ($M) ($M)6 kỳ
Clinical Trials, Product Quality, Global Workforce, EHS Safety & Sustainability
- Active Clinical Trials Sponsored by Boston Scientific (trials)3 kỳ
- Global Regulatory Quality Inspections Completed (inspections)8 kỳ
- Total Global Employees (headcount)11 kỳ
- CEO Pay Ratio (x)8 kỳ
- Total Recordable Incident Rate (TRIR, injuries per 100 FTEs)8 kỳ
- Key Manufacturing & Distribution Sites — Scope 1 & 2 Market-Based GHG Emissions (tCO2e)8 kỳ
- Key Manufacturing & Distribution Sites — Total Energy Consumed (MWh)8 kỳ
- ISO 14001:2015 Environmental Management Certified Key Sites (sites)8 kỳ
- Solid Non-Hazardous Waste Generated at Key Sites (metric tons)8 kỳ
- Total Water Incoming at Key Manufacturing & Distribution Sites (Million m3)8 kỳ
- Tier 1 Direct Suppliers Identified (suppliers)8 kỳ
- Philanthropic Cash Contributions ($M) ($M)7 kỳ
Acquired & International Subsidiaries — Self-Reported Filings (Axonics, Silk Road Medical & UK Limited)
Independent Regulatory & Industry Benchmarks (U.S. FDA openFDA, ClinicalTrials.gov & FRED)
- U.S. FDA 510(k) Premarket Notification Clearances — Boston Scientific (clearances)153 kỳ
- U.S. FDA Premarket Approval (PMA) Original & Supplement Approvals — Boston Scientific (approvals)153 kỳ
- U.S. FDA MAUDE Adverse Event MDR Reports — Boston Scientific Total (reports)153 kỳ
- NIH ClinicalTrials.gov — Boston Scientific Studies Started in Period (studies)47 kỳ
- U.S. Producer Price Index — Surgical & Medical Instrument Manufacturing (NAICS 339112, index)141 kỳ
GAAP Financial & Segment Context (Database)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Boston Scientific
- Form 10-Q — FY2026Q3 (filed 2026-11-02) ↗
- BSX FY2026Q3 Financial & Operational Highlights Presentation ↗
- BSX FY2025Q4 Financial & Operational Highlights Presentation ↗
- BSX 2025 Impact Report Data Pack (XLSX) ↗
- U.S. FDA openFDA Device Clearances, Approvals, Recalls & MAUDE MDR ↗
- Form EX21 — FY2025 (filed 2026-02-17) ↗
- BSX FY2025Q3 Financial & Operational Highlights Presentation ↗
- BSX FY2024Q4 Financial & Operational Highlights Presentation ↗
- Form 10-K — FY2021 (filed 2022-02-23) ↗
- Form 8-K_EARNINGS — FY2026Q3 (filed 2026-10-28) ↗
- Form 8-K_EARNINGS — FY2025Q4 (filed 2026-02-04) ↗
- Form 10-Q (filed 2026-11-02) ↗
See a number that looks wrong?